KR850001221A - Method for preparing cephalosporin - Google Patents

Method for preparing cephalosporin Download PDF

Info

Publication number
KR850001221A
KR850001221A KR1019840004465A KR840004465A KR850001221A KR 850001221 A KR850001221 A KR 850001221A KR 1019840004465 A KR1019840004465 A KR 1019840004465A KR 840004465 A KR840004465 A KR 840004465A KR 850001221 A KR850001221 A KR 850001221A
Authority
KR
South Korea
Prior art keywords
ester
solvent
cefuroxime
process according
crystallized
Prior art date
Application number
KR1019840004465A
Other languages
Korean (ko)
Other versions
KR910008377B1 (en
Inventor
알프레드 크리스프 하롤드 (외 3)
Original Assignee
원본미기재
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 글락소 그룹 리미티드 filed Critical 원본미기재
Publication of KR850001221A publication Critical patent/KR850001221A/en
Application granted granted Critical
Publication of KR910008377B1 publication Critical patent/KR910008377B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
    • C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음No content

Description

세팔로스포린의 제조방법Method for preparing cephalosporin

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제1도 : 결정성 세푸록심 악세틸이성체 혼합물의 누졸(Nujol)중에서의 IR분광도이다.Figure 1: IR spectroscopy in Nujol of the crystalline cefuroxime acetyl isomer mixture.

Claims (8)

유기 또는 수성용매 또는 이들의 혼합액중의 세푸록심 1-아세톡시에틸에스테르 용액으로부터 세푸록심 1-아세톡시 에틸 에스테르를 결정화하고 생성물을 분리한 후 건조시켜고 순도의 결정성 세푸록심 1-아세톡시 에틸 에스테르를 제조하는 방법.Sepuloxime 1-acetoxyethyl ester is crystallized from a cefuroxime 1-acetoxyethyl ester solution in an organic or aqueous solvent or a mixture thereof, and the product is separated, dried and purified crystalline cefuroxime 1-acetoxy ethyl. How to prepare an ester. 제1항에 있어서, 세푸록심 1-아세톡시에틸 에스테르를 약 1:1의 R:S 이성체비로 결정화하는 방법.The method of claim 1, wherein the cefuroxime 1-acetoxyethyl ester is crystallized at an R: S isomer ratio of about 1: 1. 제1항 또는 2항에 있어서, 용매로서 에스테르가 포함되는 방법.The process according to claim 1 or 2, wherein the ester is included as a solvent. 제3항에 있어서, 용매로서, 임의로 에테르 또는 지방족 또는 방향족 탄화수소와 혼합된 형태의 에스테르 또는 할로겐화된 탄화수소; 또는 물과 혼합된 형태의 케톤 또는 아마이드가 포함되는 방법.The process of claim 3, further comprising: esters or halogenated hydrocarbons in the form optionally mixed with ethers or aliphatic or aromatic hydrocarbons; Or ketones or amides in admixture with water. 제1항 또는 2항에 있어서, 용매로서, 물과 혼합된 형태의 알코올이 포함되는 방법.The process according to claim 1 or 2, wherein the solvent comprises alcohol in a form mixed with water. 제4항에 있어서, 용매를, 임의로 디이소프로필 에테르, 석유 에테르 또는 톨루엔과 혼합된 형태의 메틸 또는 에틸아세테이트중에서 선택한 방법.The process of claim 4 wherein the solvent is selected from methyl or ethyl acetate, optionally in the form of admixture with diisopropyl ether, petroleum ether or toluene. 제1항내지 6항중의 어느 하나에 있어서, 적어도 결정화단계의 후반부를 10내지 30℃에서 수행하는 방법.The process according to any one of claims 1 to 6, wherein at least the second half of the crystallization step is carried out at 10 to 30 ° C. 제1내지 7항중의 어느 하나에 있어서, 실시예에 기술된 방법.The method as described in any one of Claims 1-7 as described in an Example. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019840004465A 1983-07-29 1984-07-27 Process for preparation of celphaslosporin KR910008377B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8320521 1983-07-29
GB838320521A GB8320521D0 (en) 1983-07-29 1983-07-29 Chemical process

Publications (2)

Publication Number Publication Date
KR850001221A true KR850001221A (en) 1985-03-16
KR910008377B1 KR910008377B1 (en) 1991-10-12

Family

ID=10546505

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840004465A KR910008377B1 (en) 1983-07-29 1984-07-27 Process for preparation of celphaslosporin

Country Status (21)

Country Link
JP (1) JPH0613526B2 (en)
KR (1) KR910008377B1 (en)
AT (1) AT392470B (en)
AU (2) AU582121B2 (en)
BE (1) BE900241A (en)
CA (1) CA1265511A (en)
CH (1) CH662121A5 (en)
DE (1) DE3427828A1 (en)
DK (1) DK165505C (en)
ES (1) ES534695A0 (en)
FI (1) FI76808C (en)
FR (1) FR2549837B1 (en)
GB (2) GB8320521D0 (en)
IE (1) IE57726B1 (en)
IL (1) IL72536A (en)
NL (1) NL8402372A (en)
NO (1) NO167292C (en)
NZ (1) NZ209046A (en)
PT (1) PT78985B (en)
SE (1) SE463263B (en)
ZA (1) ZA845830B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8400024D0 (en) * 1984-01-03 1984-02-08 Glaxo Group Ltd Cephalosporin antibiotics
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US5063224A (en) * 1990-07-09 1991-11-05 Eli Lilly And Company R-cefuroxime axetil
IT1277426B1 (en) * 1995-08-03 1997-11-10 Acs Dobfar Spa BIOAVAILABLE CRYSTALLINE FORM OF CEFUROXIMA AXETIL
CN1111537C (en) * 1997-05-15 2003-06-18 第一制糖株式会社 The preparation method of highly pure crystalline form of cefuroxime axetil
KR100228264B1 (en) * 1997-08-02 1999-11-01 김선진 The synthetic method of crystalline cefuroxime axetil
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
IN186539B (en) * 1997-09-29 2001-09-29 Ranbaxy Lab Ltd
DE19907521A1 (en) * 1998-02-20 1999-11-04 Fako Ilaclari A S New crystalline form of (R,S)-cefuroxime axetil
IN190849B (en) 2000-07-17 2003-08-23 Ranbaxy Lab Ltd
AT411996B (en) 2000-09-11 2004-08-26 Sandoz Ag METHOD FOR PRODUCING CEFUROXIME IN THE FORM OF ITS N-BUTYL LAMONIUM SALTS
ITMI20011763A1 (en) * 2001-08-10 2003-02-10 Antibioticos Spa HIGH-PURITY CEFUROXIME AXELITE PREPARATION PROCESS
ITMI20011925A1 (en) * 2001-09-14 2003-03-14 Antibioticos Spa METHOD APPLICABLE ON INDUSTRIAL SCALE FOR THE PREPARATION OF CEFUROXIME AXETILE CRISTALLINO
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
CN100448879C (en) * 2004-07-22 2009-01-07 北京化工大学 Method for preparing unformed cefuroxime axetil
DE102005019458A1 (en) 2005-04-25 2006-10-26 Grünenthal GmbH Composition, useful in the preparation of pellets and the multi-particular-presentation form, comprises cefuroximaxetil and carrageenan of the group of lambda carrageenan, tau carrageenan and kappa carrageenan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1094545A (en) * 1976-02-16 1981-01-27 Michael Gregson Cephalosporin antibiotics
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
GB1598568A (en) * 1977-04-19 1981-09-23 Glaxo Lab Ltd Esters of(6r,7r)-3-carbamoyloxymethyl-7-((z)-2-(fur-2-yl)-2-methoxyiminoacetamido)-ceph-3-em-4-carboxylic acid
JPS577485A (en) * 1980-06-13 1982-01-14 Takeda Chem Ind Ltd Cephalosporin
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8400024D0 (en) * 1984-01-03 1984-02-08 Glaxo Group Ltd Cephalosporin antibiotics

Also Published As

Publication number Publication date
GB8320521D0 (en) 1983-09-01
FI843011A (en) 1985-01-30
ES8601869A1 (en) 1985-11-01
DE3427828A1 (en) 1985-02-14
GB2145409A (en) 1985-03-27
GB2145409B (en) 1987-02-18
SE463263B (en) 1990-10-29
DK165505C (en) 1993-04-19
ZA845830B (en) 1986-03-26
NL8402372A (en) 1985-02-18
FR2549837A1 (en) 1985-02-01
FI843011A0 (en) 1984-07-27
NO167292B (en) 1991-07-15
PT78985A (en) 1984-08-01
IL72536A (en) 1988-01-31
NZ209046A (en) 1988-02-29
FI76808C (en) 1988-12-12
CA1265511A (en) 1990-02-06
IL72536A0 (en) 1984-11-30
DK165505B (en) 1992-12-07
JPH0613526B2 (en) 1994-02-23
ATA244484A (en) 1990-09-15
KR910008377B1 (en) 1991-10-12
SE8403897D0 (en) 1984-07-27
DK366684D0 (en) 1984-07-27
IE57726B1 (en) 1993-03-24
ES534695A0 (en) 1985-11-01
NO843055L (en) 1985-01-30
AU3125684A (en) 1985-01-31
SE8403897L (en) 1985-01-30
FI76808B (en) 1988-08-31
CH662121A5 (en) 1987-09-15
AU3660189A (en) 1989-10-05
GB8419202D0 (en) 1984-08-30
NO167292C (en) 1991-10-23
DK366684A (en) 1985-01-30
FR2549837B1 (en) 1986-12-26
AU634965B2 (en) 1993-03-11
JPS6075484A (en) 1985-04-27
PT78985B (en) 1986-10-23
BE900241A (en) 1985-01-28
IE841938L (en) 1985-01-29
AT392470B (en) 1991-04-10
AU582121B2 (en) 1989-03-16

Similar Documents

Publication Publication Date Title
KR850001221A (en) Method for preparing cephalosporin
DE3680090D1 (en) CONTINUOUS PROCESS FOR THE FERMENTATIVE PRODUCTION OF ORGANIC ACIDS.
GB1511219A (en) Solvents for and purification of chitin
KR960703842A (en) PROCESS FOR THE CRYSTALLIZATION OF IOPAMIDOL
IE781955L (en) Isolating pseudomonic acid
SE429341B (en) PROCEDURE FOR SEPARATION AND RECYCLING OF FURFURAL AND ORGANIC VOLATIC ACIDS, LIKE ETHIC ACID AND ANTIC ACID, BY THE FURFURAL PREPARATION PROCESS
JPS54119494A (en) Preparation of cephalosporin compound
FI881038A0 (en) NY CRYSTALLINE CEFADROXY OTHERS FOERFARANDE FOER DESS FRAMSTAELLNING.
KR860002512A (en) Method for preparing cephalosporin intermediate
SE7413246L (en)
ES8203015A1 (en) Solvate of amoxicillin, process for the preparation thereof and process for the preparation of injectable preparations from this solvate.
GB1549533A (en) Process for the purification of phthalic anhydride
GB1121356A (en) Improvements in or relating to the manufacture of carbocyclic peroxycarboxylic acids
JPS5612352A (en) Ai-77, medically permissible salt thereof and their preparation
IE44886L (en) Quinoline carboxylic acid esters
JPS5618936A (en) Production of phenylacetic acid
JPS5227792A (en) Synthesis of cephalosporin compounds
JPS5283750A (en) Crystals of 5-amino-4-imidazol-carboxyamide
KR920004350A (en) Process for the preparation of esters from 5-alkylpyridine-2,3-dicarboxylic acids
JPS51125309A (en) Process for preparation of glycerine
JPS5517351A (en) Production of sesquiterpene derivative
GB902387A (en) Purification of bis-hydroxyethyl phthalates
JPS5693737A (en) Nitrocellulose composition and production thereof
JPS5671080A (en) Novel mandelic tetrazol-5-ylthiol ester and its preparation
JPS54119468A (en) Novel antibiotic, nanaomycin e and its preparation

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20011005

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee